IXICO plc Result of General Meeting - Amended (6086B)
September 21 2018 - 10:46AM
UK Regulatory
TIDMIXI
RNS Number : 6086B
IXICO plc
21 September 2018
The following amendment has been made to the 'Results of General
Meeting' announcement released on 21/09/2018 at 11:00 under RNS No
5577B.
Updated contact details.
All other details remain unchanged.
The full amended text is shown below.
IXICO plc
("IXICO" or the "Company")
Result of General Meeting
IXICO plc (AIM: IXI), the data science company delivering
insights in neuroscience, is pleased to announce that at the
General Meeting held earlier today, the Resolutions to approve the
Capital Reorganisation were duly passed.
Application has been made to AIM for the New Ordinary Shares to
be admitted to trading on AIM. It is expected that such Admission
will become effective and that dealings will commence in the New
Ordinary Shares at 8.00 am on 24 September 2018.
Following Admission the Company's issued share capital will
consist of 46,777,000 New Ordinary Shares of 1 pence each. The
total number of voting rights in the Company will therefore be
46,777,000 New Ordinary Shares.
Unless otherwise stated, defined terms in this announcement not
otherwise defined shall have the same meaning as is ascribed to
them in the circular posted to shareholders on 3 September
2018.
For further information please contact:
IXICO plc
Giulio Cerroni, Chief Executive Officer Tel: +44 20 3763
Susan Lowther, Chief Financial Officer 7499
Shore Capital (Nomad and Broker) Tel: +44 20 7408
Edward Mansfield / Anita Ghanekar / Daniel 4090
Bush
FTI Consulting Limited (Investor Relations) Tel: +44 20 3727
Simon Conway/Mo Noonan 1000
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
mission is to transform the progression of our clients'
neurodegenerative therapeutic pipeline through the application of
novel medical imaging and mobile health digital technologies.
IXICO's specialist data analytics services are used by the
global pharmaceutical industry to interpret brain scan data and
digital biomarkers to enable better trial design, site
qualification, patient selection and clinical outcomes. We provide
technology-enabled services across all phases of clinical trial
process evaluation. Our integrated digital platform provides a
scalable and secure infrastructure for the capture and analysis of
regulatory compliant clinical data to enable clients to make rapid,
better informed decisions. IXICO is also collaborating with
partners to develop new analytical techniques and companion digital
health products targeted at improving patient outcomes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ROMLLFVEASILFIT
(END) Dow Jones Newswires
September 21, 2018 11:46 ET (15:46 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024